Amber Roberts

Aspen Neuroscience will Present at the Annual iPSC-Derived Cell Therapies Summit

by
IPSC Summit Logo 2022

We are looking forward to presenting this week at the annual iPSC-Derived Cell Therapies Summit in Boston. Xiaokui Zhang, PhD, Aspen’s Chief Scientific officer will serve as a panel member on Tuesday, December 6th at 8:30 a.m. during “Industry Leaders’ Fireside Chat: Taking a Look at the Current Learnings from iPSC-Derived Cell Therapies & Determining Future … Read more

Aspen Neuroscience does not make determination on patient eligibility for clinical trials and all trial related enrollment and eligibility decisions are made by clinical trial sites per protocol under the direction of a Principal Investigator. ANPD001 is investigational and is not yet approved by the FDA. At this time, Aspen Neuroscience does not offer or participate in compassionate use or expanded access programs for ANPD001.

Aspen Neuroscience’s David Tastad, PhD, Presented at the Annual Society for Neuroscience Meeting

by
sfn1

Aspen Neuroscience’s David Tastad, PhD, presented the poster “Dopamine Neuron Regulation,” at the annual Society for Neuroscience (SFN) meeting on Sunday, November 13th. The presentation explored functional characterization of GBA1 mutations in iPSC-derived midbrain dopaminergic neurons.  “There was a great turnout at David’s poster at SFN 2022, a session packed with invigorating and collaborative discussions, … Read more

Aspen Neuroscience does not make determination on patient eligibility for clinical trials and all trial related enrollment and eligibility decisions are made by clinical trial sites per protocol under the direction of a Principal Investigator. ANPD001 is investigational and is not yet approved by the FDA. At this time, Aspen Neuroscience does not offer or participate in compassionate use or expanded access programs for ANPD001.

CMC Expert Kim Raineri Joins Aspen Neuroscience as Chief Technology Officer

by
Kim Raineri, CTO

SAN DIEGO, Oct. 19, 2022 – Aspen Neuroscience, Inc., a private biotechnology company developing the first autologous neuron replacement therapies to treat Parkinson’s disease (PD), announced that Kim Raineri has joined the company as Chief Technology Officer and as a member of the company’s executive team.

Aspen Neuroscience does not make determination on patient eligibility for clinical trials and all trial related enrollment and eligibility decisions are made by clinical trial sites per protocol under the direction of a Principal Investigator. ANPD001 is investigational and is not yet approved by the FDA. At this time, Aspen Neuroscience does not offer or participate in compassionate use or expanded access programs for ANPD001.

NeuriTest™ Presented Publicly for the First Time at the International Society for Stem Cell Research Annual Meeting

by
Aspen Roy IMG 5026 Final Square scaled

SAN DIEGO, June 22, 2022 — Aspen Neuroscience, Inc. Director of Bioinformatics, Roy Williams, Ph.D., presented NeuriTest™ for the first time publicly last week at the 2022 International Society for Stem Cell Research (ISSCR) Annual Meeting in San Francisco, Calif. Dr. Williams’ podium presentation, “NeuriTest: A Bioinformatics-based Tool for Quality Control of iPSC-derived Dopamine Neuron Precursors for Transplantation,” featured the advanced … Read more

Aspen Neuroscience does not make determination on patient eligibility for clinical trials and all trial related enrollment and eligibility decisions are made by clinical trial sites per protocol under the direction of a Principal Investigator. ANPD001 is investigational and is not yet approved by the FDA. At this time, Aspen Neuroscience does not offer or participate in compassionate use or expanded access programs for ANPD001.

Aspen Neuroscience Pursues Autologous Cell Therapies for Parkinson’s with $147.5M Series B

by
Aspen Neuroscience Series B

The Scripps Research spinout eyes 2023 for dosing of its first patients with its first product, designed to treat idiopathic Parkinson’s disease.

Aspen Neuroscience does not make determination on patient eligibility for clinical trials and all trial related enrollment and eligibility decisions are made by clinical trial sites per protocol under the direction of a Principal Investigator. ANPD001 is investigational and is not yet approved by the FDA. At this time, Aspen Neuroscience does not offer or participate in compassionate use or expanded access programs for ANPD001.

Aspen Neuroscience collects large Series B to compete against Bayer’s Parkinson’s cell therapy

by

Damien McDevitt thinks frequently about the name Aspen Neuroscience. Specifically, should the neuroscience portion be dropped as the San Diego biotech considers expanding beyond the CNS?

Aspen Neuroscience does not make determination on patient eligibility for clinical trials and all trial related enrollment and eligibility decisions are made by clinical trial sites per protocol under the direction of a Principal Investigator. ANPD001 is investigational and is not yet approved by the FDA. At this time, Aspen Neuroscience does not offer or participate in compassionate use or expanded access programs for ANPD001.

Aspen Neuroscience leverages stem cell biology and advanced genomics to provide the world’s first autologous induced pluripotent stem cell (iPSC)-derived neuron replacement therapy for Parkinson's disease.

Contact

10835 Road to the Cure
Ste. 100
San Diego, CA 92121

© 2025 Aspen Neuroscience - All Rights Reserved